| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Angiocrine factors released from endothelial cells directly can regulate hematopoiesis and leukemia/lymphoma growth. The serine protease tissue type plasminogen activator, a classical fibrinolytic factor, its endogenous inhibitor plasminogen activator inhibitor-1 and its downstream targets matrix metalloproteases can be released from endothelial cells, and therefore also can be regarded as angiocrine factors. We could show that angiocrine factors regulate leukemia/lymphoma growth and control inflammatory diseases, thereby preventing tissue damage, and disease-associated death in murine models of inflammation. Our recent studies demonstrate that pharmacological and genetic control of the fibrinolytic system is a new therapeutic approach to treat inflammation-associated leukemia/lymphoma and associated diseases. Therefore, the initially proposed action plan for this research was performed as proposed and the targets achieved.
|
